Outcomes of interferon α and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminases
Outcomes of interferon α and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminases
复制标题
干扰素α和利巴韦林治疗血清转氨酶正常的慢性丙型肝炎患者的结果
DOI：
--
复制
发表时间：
2003
期刊：
影响因子：
--
通讯作者：
T. Wright
中科院分区：
文献类型：
--
作者：
C. Hui;A. Monto;T. Belaye;E. Lau;T. Wright
前言：关于干扰素联合利巴韦林治疗丙氨酸氨基转移酶(ALT)正常的慢性丙型肝炎患者的治疗结果的信息有限。目的：本研究的目的是比较ALT正常组(n=52)和ALT升高组(n=53)患者接受干扰素联合利巴韦林治疗的疗效，并记录ALT正常患者病情明显恶化的比率。结果：治疗48周时，ALT正常组31例(59.6%)和ALT升高组30例(56.6%)未检出丙型肝炎病毒(HCVRNA)(p=0.75)。持续病毒学应答(SVR)：ALT正常组20例(38.5%)，ALT升高组21例(39.6%)(P=0.90)。治疗72周后，ALT正常组患者平均随访29.8个月(IQR为20.8~36.2个月)，ALT升高组患者平均随访26.1个月(IQR 17.7~36.3个月)(p=0.20)。在ALT正常组中没有SVR的患者中，只有3例(9.4%)患者在治疗后ALT水平持续升高。结论：与ALT升高的患者相比，ALT正常的患者联合应用干扰素和利巴韦林的SVR相似。在ALT水平正常的患者中，病毒学上对治疗无反应导致血清ALT水平仅在一小部分人中出现新的升高。
Introduction: Information on treatment outcomes with interferon plus ribavirin combination therapy in chronic hepatitis C patients with normal alanine aminotransaminase (ALT) levels is limited. Aim: The aims of this study were to assess outcomes of treatment with interferon plus ribavirin in patients with normal ALT levels (normal ALT group, n=52) compared with those with elevated ALT levels (raised ALT group, n=53), and to document the rate at which patients with normal ALT levels have an apparent worsening of disease, as shown by increases in ALT levels. Results: At the end of treatment (week 48), 31 patients (59.6%) in the normal ALT group and 30 patients (56.6%) in the raised ALT group had undetectable hepatitis C virus (HCV) RNA (p=0.75). A sustained virological response (SVR) was achieved in 20 patients (38.5%) in the normal ALT group and in 21 patients (39.6%) in the raised ALT group (p=0.90). Patients were subsequently followed up for a median of 29.8 (interquartile range 25th–75th percentile (IQR) 20.8–36.2) months in the normal ALT group and for a median of 26.1 (IQR 17.7–36.3) months in the raised group (p=0.20) after week 72 of treatment. Among patients without SVR in the normal ALT group, only three patients (9.4%) developed persistently raised ALT levels following therapy. Conclusions: Combination therapy with interferon plus ribavirin is associated with a similar SVR in patients with normal ALT levels compared with those with elevated ALT levels. In patients with normal ALT levels, virological non-response to therapy results in new elevations in serum ALT levels in a small minority only.
登录
查看更多内容
酒精性肝硬化患者的转氨酶水平正常或接近正常。
DOI：
10.1016/j.amjms.2021.09.012
发表时间：
2022
期刊：
The American journal of the medical sciences
影响因子：
--
作者：
Sullivan,MaryKate;Daher,HalimBou;Rockey,DonC
通讯作者：
Rockey,DonC
影响因子：
1.9
作者：
J. Barrio;M. Garcia-bengoechea;J. Emparanza;J. Arenas
通讯作者：
J. Barrio;M. Garcia-bengoechea;J. Emparanza;J. Arenas
DOI：
10.1159/000332385
发表时间：
2012-01-01
期刊：
HEPATITIS C IN RENAL DISEASE, HEMODIALYSIS AND TRANSPLANTATION
影响因子：
--
作者：
Morales, Jose M.;Bloom, Roy;Roth, David
通讯作者：
Roth, David
影响因子：
158.5
作者：
McHutchison, JG;Gordon, SC;Albrecht, JK
通讯作者：
Albrecht, JK
影响因子：
158.5
作者：
Fried, MW;Shiffman, ML;Yu, J
通讯作者：
Yu, J